Weekly Research Analysts’ Ratings Updates for Phathom Pharmaceuticals (PHAT)

Several analysts have recently updated their ratings and price targets for Phathom Pharmaceuticals (NASDAQ: PHAT):

• 4/21/2025 – Phathom Pharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.
• 4/17/2025 – Phathom Pharmaceuticals had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $12.00 to $10.00. They now have a “neutral” rating on the stock.
• 4/9/2025 – Phathom Pharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.
• 4/2/2025 – Phathom Pharmaceuticals had its “buy” rating reaffirmed by analysts at Guggenheim.
• 4/2/2025 – Phathom Pharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.
• 3/10/2025 – Phathom Pharmaceuticals had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $18.00 to $12.00. They now have a “neutral” rating on the stock.
• 3/7/2025 – Phathom Pharmaceuticals was given a new $18.00 price target on by analysts at Guggenheim.
• 3/7/2025 – Phathom Pharmaceuticals had its “buy” rating reaffirmed by analysts at Craig Hallum.
• 3/7/2025 – Phathom Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $28.00 price target on the stock.
• 3/6/2025 – Phathom Pharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.
• 2/25/2025 – Phathom Pharmaceuticals was upgraded by analysts at Cantor Fitzgerald to a “strong-buy” rating.

Phathom Pharmaceuticals Trading Up 1.5 %

Shares of NASDAQ:PHAT opened at $3.96 on Wednesday. The firm has a 50 day simple moving average of $5.24 and a 200-day simple moving average of $8.43. Phathom Pharmaceuticals, Inc. has a twelve month low of $3.81 and a twelve month high of $19.71. The company has a market capitalization of $275.76 million, a PE ratio of -0.70 and a beta of 0.35.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. GAMMA Investing LLC grew its position in Phathom Pharmaceuticals by 797.2% during the 1st quarter. GAMMA Investing LLC now owns 4,558 shares of the company’s stock worth $29,000 after purchasing an additional 4,050 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new position in Phathom Pharmaceuticals in the 4th quarter valued at about $74,000. Teacher Retirement System of Texas purchased a new stake in Phathom Pharmaceuticals during the 4th quarter valued at approximately $90,000. Rafferty Asset Management LLC acquired a new stake in Phathom Pharmaceuticals during the 4th quarter worth approximately $90,000. Finally, Versor Investments LP acquired a new stake in Phathom Pharmaceuticals during the 4th quarter worth approximately $101,000. Hedge funds and other institutional investors own 99.01% of the company’s stock.

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.